Novartis AG Stock price

Equities

NOVN

CH0012005267

Pharmaceuticals

Real-time Estimate Cboe Europe 04:34:44 2023-12-08 am EST Intraday chart for Novartis AG 5-day change 1st Jan Change
83.9 CHF -0.41% -1.69% +0.42%
Sales 2023 * 46.23B 40.45B Sales 2024 * 47.51B 41.57B Capitalization 198B 173B
Net income 2023 * 9.82B 8.6B Net income 2024 * 10.29B 9.01B EV / Sales 2023 *
4,55x
Net Debt 2023 * 12.84B 11.24B Net Debt 2024 * 12.39B 10.84B EV / Sales 2024 *
4,42x
P/E ratio 2023 *
18,7x
P/E ratio 2024 *
17,7x
Employees 101,703
Yield 2023 *
3,68%
Yield 2024 *
3,84%
Free-Float 86.85%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.34%
1 week-1.67%
Current month-1.37%
1 month-1.10%
3 months-4.73%
6 months-7.10%
Current year+0.43%
More quotes
1 week
83.63
Extreme 83.63
86.41
1 month
83.09
Extreme 83.09
86.79
Current year
73.74
Extreme 73.74
94.77
1 year
73.74
Extreme 73.74
94.77
3 years
72.84
Extreme 72.84
94.77
5 years
65.09
Extreme 65.09
96.38
10 years
65.09
Extreme 65.09
103.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 47 2004
Director of Finance/CFO 58 2002
Chief Tech/Sci/R&D Officer 61 2022
Members of the board TitleAgeSince
Director/Board Member 61 2012
Director/Board Member 64 2020
Chairman 67 2012
More insiders
Date Price Change Volume
23-12-08 83.94 -0.37% 334 689
23-12-07 84.25 -0.75% 2,504,562
23-12-06 84.89 -0.20% 3,666,617
23-12-05 85.06 -1.25% 3,492,673
23-12-04 86.14 +0.89% 2,761,427

Delayed Quote Swiss Exchange, December 08, 2023 at 03:33 am EST

More quotes
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (81.7%): used to treat cardiovascular, respiratory, and dermatological diseases, gastrointestinal disorders, cancers, central nervous system disorders, hormone imbalances, etc.; - generic drugs (18.3%; Sandoz). Net sales are distributed geographically as follows: Europe (36.5%), the United States (34.9%), Asia/Africa/Australasia (20.9%), Canada and Latin America (7.7%).
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
96.11USD
Average target price
105.75USD
Spread / Average Target
+10.03%
Consensus
1st Jan change Capi.
+0.43% 198 B $
+60.80% 529 B $
+41.41% 430 B $
-12.03% 374 B $
-6.37% 263 B $
-8.44% 261 B $
-13.60% 229 B $
-9.56% 197 B $
-44.13% 162 B $
+3.30% 145 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Novartis AG - Swiss Exchange
As early as today, start finding the best investment opportunities!
Optimize my profits
fermer